Syndax Pharmaceuticals, Inc.
SNDX
$16.24
$0.402.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,866.34% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,133.71% | -- | -- | -- | -- |
| Cost of Revenue | 41.19% | 44.88% | 44.20% | 136.63% | 310.97% |
| Gross Profit | 11.36% | -10.98% | -25.84% | -114.96% | -300.90% |
| SG&A Expenses | 66.76% | 78.10% | 80.63% | 95.03% | 103.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.05% | 47.04% | 58.01% | 73.75% | 68.62% |
| Operating Income | -17.64% | -30.45% | -47.71% | -65.50% | -66.60% |
| Income Before Tax | -26.85% | -37.64% | -52.25% | -68.71% | -64.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.85% | -37.64% | -52.25% | -68.71% | -64.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.85% | -37.64% | -52.25% | -68.71% | -64.70% |
| EBIT | -17.64% | -30.45% | -47.71% | -65.50% | -66.60% |
| EBITDA | -17.65% | -30.45% | -47.72% | -65.51% | -66.61% |
| EPS Basic | -15.38% | -19.97% | -25.83% | -40.47% | -38.68% |
| Normalized Basic EPS | -15.38% | -19.97% | -25.83% | -40.48% | -38.69% |
| EPS Diluted | -15.15% | -19.83% | -25.70% | -40.63% | -38.85% |
| Normalized Diluted EPS | -15.38% | -19.97% | -25.83% | -40.48% | -38.69% |
| Average Basic Shares Outstanding | 9.87% | 15.29% | 21.41% | 20.70% | 18.99% |
| Average Diluted Shares Outstanding | 9.87% | 15.29% | 21.41% | 20.70% | 18.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |